AC Immune (NASDAQ:ACIU) Receives Average Recommendation of “Hold” from Analysts

AC Immune (NASDAQ:ACIU) has been given an average recommendation of “Hold” by the five brokerages that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $7.50.

A number of analysts recently commented on ACIU shares. BTIG Research restated a “buy” rating and set a $8.00 price target on shares of AC Immune in a research note on Monday, May 4th. Jefferies Financial Group reiterated a “buy” rating and issued a $7.00 price objective on shares of AC Immune in a research note on Friday, March 13th. HC Wainwright restated a “buy” rating on shares of AC Immune in a research report on Wednesday. Finally, Weiss Ratings lowered AC Immune from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 8th.

Insider Transactions at AC Immune

In other AC Immune news, CEO Andrea Pfeifer sold 10,000 shares of AC Immune stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $2.79, for a total transaction of $27,900.00. Following the completion of the transaction, the chief executive officer owned 3,820,288 shares of the company’s stock, valued at $10,658,603.52. The trade was a 0.26% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 4.60% of the company’s stock.

Hedge Funds Weigh In On AC Immune

Hedge funds have recently bought and sold shares of the company. EFG International AG bought a new stake in AC Immune during the 4th quarter worth approximately $41,000. Private Advisor Group LLC bought a new position in AC Immune in the 3rd quarter valued at $48,000. Sei Investments Co. purchased a new position in shares of AC Immune during the 2nd quarter valued at $51,000. Goldman Sachs Group Inc. increased its holdings in shares of AC Immune by 46.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock worth $58,000 after purchasing an additional 5,920 shares during the period. Finally, Susquehanna International Group LLP purchased a new stake in shares of AC Immune in the third quarter worth $63,000. Hedge funds and other institutional investors own 51.36% of the company’s stock.

AC Immune Stock Performance

Shares of ACIU stock traded down $0.09 on Wednesday, hitting $2.30. 74,616 shares of the stock were exchanged, compared to its average volume of 305,319. The company has a current ratio of 0.87, a quick ratio of 1.02 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $233.56 million, a PE ratio of -2.81 and a beta of 1.59. AC Immune has a one year low of $1.94 and a one year high of $4.00. The firm’s 50 day moving average is $2.66 and its two-hundred day moving average is $2.95.

AC Immune (NASDAQ:ACIU) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.01. The business had revenue of $1.40 million for the quarter, compared to analysts’ expectations of $0.33 million. AC Immune had a negative return on equity of 125.26% and a negative net margin of 1,788.02%. Sell-side analysts expect that AC Immune will post -0.84 earnings per share for the current fiscal year.

About AC Immune

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.